Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score

Circulation

Volumn 108, Issue 2, 2003, Pages 161-165

  Albert, Michelle A ^a   Glynn, Robert J ^b   Ridker, Paul M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

Inflammation; Prevention; Risk factors

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

AGE DISTRIBUTION; AGED; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION;

EID: 0038447922     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000080289.72166.CF     Document Type: Article

References (20)

1. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
2. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
3. D'Agostino RB, Grundy S, Sullivan LM, et al. for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
4. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001:103;357-362.
5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
6. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
7. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
8. Albert MA, Staggers J, Chew P, et al. The Pravastatin Inflammation/CRP Evaluation (PRINCE): rationale and design. Am Heart J. 2001;141:893-898.
9. Albert MA, Danielson E, Rifai N, et al, for the PRINCE Investigators. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
10. Roberts WL, Molton L, Law TC, et al. Evaluation of nine automated high sensitivity C-reactive protein methods: implications for clinical and epidemiological application, II. Clin Chem. 2001;47:418-425.
11. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and homeostasis in elderly women. Arterioscler Thromb Vasc Biol. 1999;19:893-899.
12. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713-716.
13. Koenig W, Sund M, Froelich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
14. Ridker PM, Rifai N, Clearfield M, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
15. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
16. Lowe G, Upton M, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional survey. Thromb Haemost. 2001;86:550-556.
17. Shepard J, Cobb SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
18. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
19. Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
20. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J. 2001;22:2135-2137.